drugset / Trial / NCT02422381
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2
Active not recruiting
16 enrolled
Providence Health & Services
Merck Sharp & Dohme LLC · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine. The study will also try to identify the best dose of MK-3475 to give in combination with gemcitabine.
Timeline
- Start
- 2015-07-20
- Primary completion
- 2019-01-09
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |